We aim to create an inspiring environment in which outstanding scientists can excel. By providing state-of-the-art core facilities and support for our researchers, we foster new collaborations that spark discoveries about fundamental cellular processes and their relevance in disease.
A study from the Owen lab led by Bernard Kelly has determined a new structure of the adaptor AP2 that reveals a clathrin-binding β2 hinge region. Using this, they show that AP2 regulates clathrin polymerization, and thus clathrin-mediated endocytosis, through a membrane-activated switch.
The Lehner and Nathan labs report in the Journal of Cell Biology that specific tail-anchored proteins can be cleaved within the membrane by signal peptide peptidase (SPP), and thereby targeted for turnover.
David Rubinsztein has been included in a list released by Thomson Reuters of the most highly cited researchers worldwide across 21 fields of the sciences and social sciences. This is based on his studies published between 2002 and 2012 in two categories of science (Biology & Biochemistry and Molecular Biology & Genetics), which have provided a "mark of exceptional impact".
In an interview with Type 1 Discovery magazine, Frank Waldron-Lynch outlines the defining features of the DILT1D clinical trial being conducted by the JDRF/Wellcome Trust Diabetes and Inflammation Laboratory, and the successful completion of its patient recruitment a year ahead of schedule.
you use our web site. We may also use external analysis systems which may
set additional cookies to perform their analysis.These cookies (and any
others in use) are detailed in our site privacy and cookie policies and are
integral to our web site. You can delete or disable these cookies in your
web browser if you wish but then our site may not work correctly.